Osimertinib | List of Frontiers open access articles

Methods

Published on 22 Jul 2022

Instability Mechanism of Osimertinib in Plasma and a Solving Strategy in the Pharmacokinetics Study

in Drug Metabolism and Transport

Zheng Yuan
Xin Yu
Siyang Wu
Xiaonan Wu
Qiutao Wang
Wenhao Cheng
Weiyu Hu
Chen Kang
Wei Yang
Yingfei Li

Frontiers in Pharmacology

doi 10.3389/fphar.2022.928983

10,383 views
21 citations

Original Research

Published on 30 May 2023

Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels

in Pharmacology of Anti-Cancer Drugs

Peiwen Li
Xiaohui Tian
Gongxin Wang
Enshe Jiang
Yanming Li
Guoliang Hao

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1177003

5,500 views
20 citations

Case Report

Published on 26 Apr 2021

Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review

in Thoracic Oncology

Alessandro Leonetti
Roberta Minari
Giulia Mazzaschi
Letizia Gnetti
Silvia La Monica
Roberta Alfieri
Nicoletta Campanini
Michela Verzè
Andrea Olivani
Luigi Ventura

Frontiers in Oncology

doi 10.3389/fonc.2021.642190

11,461 views
42 citations

Original Research

Published on 10 Nov 2020

A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy

in Systems Microbiology

Jing Cong
Yuguang Zhang
Yadong Xue
Chuantao Zhang
Mingjin Xu
Dong Liu
Ruiyan Zhang
Hua Zhu

Frontiers in Microbiology

doi 10.3389/fmicb.2020.583525

5,200 views
11 citations

Case Report

Published on 05 Apr 2022

Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report

in Pharmacology of Anti-Cancer Drugs

Wang Shujun
Lou Lili
Yang Lei
Wang Feng
Zhan Hefeng

Frontiers in Pharmacology

doi 10.3389/fphar.2022.854277

6,035 views
6 citations

Original Research

Published on 20 Oct 2021

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib

in Thoracic Oncology

Yu Wang
Songtao Liu
Alei Feng
Huan Luo
Jinwei Hu
Kai Wang
Wei Dong

Frontiers in Oncology

doi 10.3389/fonc.2021.727312

4,117 views
2 citations

Original Research

Published on 26 Aug 2022

Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation

in Pharmacology of Anti-Cancer Drugs

Shanliang Hu
Congjie Wang
Chunsheng Wang
Kewei Zhao
Zhen Wang
Wei Dong

Frontiers in Pharmacology

doi 10.3389/fphar.2022.986962

2,398 views
1 citation

Original Research

Published on 05 May 2021

Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study

in Molecular Diagnostics and Therapeutics

Xue Yang
Yang Xia
Liyan Xu
Li Liang
Minglei Zhuo
Meina Wu
Tongtong An
Ziping Wang
Yuyan Wang
Jianjie Li

Frontiers in Molecular Biosciences

doi 10.3389/fmolb.2021.639892

6,111 views
19 citations

Case Report

Published on 30 Jun 2025

Potential interactions between traditional Chinese medicine and osimertinib: a Case Report

in Pharmacology of Anti-Cancer Drugs

Min Zhang
Huiwen Ma
Wanyi Chen
Zhongzhen Yuan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1596913

3,534 views
1 citation

Case Report

Published on 23 Jan 2025

Rare skin adverse reactions induced by osimertinib: a case report and literature review

in Thoracic Oncology

Ye Zhang
Mingzhu Ling
Min Wang
Ye Chen
Liting Zhang

Frontiers in Oncology

doi 10.3389/fonc.2025.1523541

4,446 views
3 citations

Mini Review

Published on 14 Apr 2022

Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review

in Cancer Molecular Targets and Therapeutics

Chengyang Song
Xueying Yang

Frontiers in Oncology

doi 10.3389/fonc.2022.834585

7,255 views
7 citations

Original Research

Published on 17 Oct 2022

Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis

in Thoracic Oncology

Yin Shi
Rui Pei
Shao Liu

Frontiers in Oncology

doi 10.3389/fonc.2022.833773

4,849 views
3 citations

Original Research

Published on 17 Apr 2025

LINC01559 drives osimertinib resistance in NSCLC through a ceRNA network regulating miR-320a/IGF2BP3 axis

in Pharmacology of Anti-Cancer Drugs

Leidi Xu
Yibo Zhang
Liangliang Xing
Ying Zhou
Ning Chang
Hangtian Xi
Xiangrui Xu
Jian Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1592846

2,638 views
4 citations

Systematic Review

Published on 11 Aug 2025

What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review

in Drugs Outcomes Research and Policies

Chuang Yang
Yunfei Wang
Yiyong Sun
Ying Sun
Rongyu Zhang
Chengjun Wang
Yanan Song
Wen Zhao
Jisheng Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1572115

4,796 views

Case Report

Published on 15 Apr 2021

Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment

in Molecular and Cellular Oncology

Hong-Shuai Li
Guang-Jian Yang
Yan Wang

Frontiers in Oncology

doi 10.3389/fonc.2021.649843

5,595 views
15 citations

Original Research

Published on 16 Feb 2023

Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer

in Cancer Immunity and Immunotherapy

Ziying Lin
Qiwei Wang
Tao Jiang
Weihua Wang
Jean J. Zhao

Frontiers in Immunology

doi 10.3389/fimmu.2023.1077203

8,614 views
33 citations

Articles

Instability Mechanism of Osimertinib in Plasma and a Solving Strategy in the Pharmacokinetics Study

Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels

Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review

A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy

Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib

Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation

Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study

Potential interactions between traditional Chinese medicine and osimertinib: a Case Report

Rare skin adverse reactions induced by osimertinib: a case report and literature review

Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review

Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis

LINC01559 drives osimertinib resistance in NSCLC through a ceRNA network regulating miR-320a/IGF2BP3 axis

What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review

Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment

Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer